BioSpace News Archive

Acer Therapeutics Inc. (Nasdaq: ACER), today announced that Acer’s management team will participate in the upcoming 11th Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright BioConnect Virtual Conference.

ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, the world’s first bio-degradable vitreous substitute, was presented by Dr. Andrew Chang, MD, Ph.D on December 11, 2021 at the 14th Asia-Pacific Vitreo-Retina Society (“APVRS”) Congress.

According to Emergen Research, the global interventional cardiology devices market size was USD 13.72 billion in 2020 and is expected to reach USD 26.84 billion in 2028 and register a revenue CAGR of 8.7% during the forecast period, 2021-2028.

According to Emergen Research, the global nanotechnology market size was USD 75.80 Billion in 2020 and is expected to reach USD 290.93 Billion in 2028 and register a revenue CAGR of 18.3% during the forecast period, 2021-2028.

According to Emergen Research, the global orthopedic biomaterial market size was USD 14.39 Billion in 2020 and is expected to reach USD 29.62 Billion in 2028 and register a revenue CAGR of 9.4% during the forecast period, 2021-2028.

According to Emergen Research, the global RNA transcriptomics market size was USD 4.46 Billion in 2020 and is expected to reach USD 12.46 Billion in 2028 and register a revenue CAGR of 13.6% during the forecast period, 2021-2028.

Rising number of people suffering from endometriosis, increasing demand for novel drugs and hormonal therapies, and ongoing R&D activities for advanced endometriosis treatments are among the key factors expected to drive market revenue growth.

Increasing use of industrial films in pharmaceutical product packaging and rising demand for pharma & healthcare products worldwide are among the key factors expected to drive market revenue growth.

BetterLife today announced that its wholly-owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), has signed an agreement with an European-based investor group to complete a non-brokered financing of up to US$5.0 million by way of private placement of Altum’s common shares.

Sage Institute for Psychedelic Therapy today announced that founding Executive Director Genesee Herzberg, PsyD, and Jason Butler, PhD, the Institute’s training director and also a co-founder, have left the organization to pursue other professional interests and opportunities.